Brazilian regulation of biosimilar products: what is important to know (2022)
Oliveira, Sílvia Helena Cestari de; Alegria, Marcos Castanheira; Stephano, Marco Antônio 
Source: BioPharm International. Unidade: FCF
Assunto: MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Sílvia Helena Cestari de e ALEGRIA, Marcos Castanheira e STEPHANO, Marco Antônio. Brazilian regulation of biosimilar products: what is important to know. BioPharm International, v. 35, n. 9, p. 30–37, 2022Tradução . . Disponível em: https://www.biopharminternational.com/view/brazilian-regulation-of-biosimilar-products-what-is-important-to-know. Acesso em: 29 jan. 2026.APA
Oliveira, S. H. C. de, Alegria, M. C., & Stephano, M. A. (2022). Brazilian regulation of biosimilar products: what is important to know. BioPharm International, 35( 9), 30–37. Recuperado de https://www.biopharminternational.com/view/brazilian-regulation-of-biosimilar-products-what-is-important-to-knowNLM
Oliveira SHC de, Alegria MC, Stephano MA. Brazilian regulation of biosimilar products: what is important to know [Internet]. BioPharm International. 2022 ; 35( 9): 30–37.[citado 2026 jan. 29 ] Available from: https://www.biopharminternational.com/view/brazilian-regulation-of-biosimilar-products-what-is-important-to-knowVancouver
Oliveira SHC de, Alegria MC, Stephano MA. Brazilian regulation of biosimilar products: what is important to know [Internet]. BioPharm International. 2022 ; 35( 9): 30–37.[citado 2026 jan. 29 ] Available from: https://www.biopharminternational.com/view/brazilian-regulation-of-biosimilar-products-what-is-important-to-know
